The ENERGY study is for adults (ages 18 and up) with warm Autoimmune Hemolytic Anemia (wAIHA) who are currently receiving treatment or have previously received treatment. The goal of the study is to see if the study drug, Nipocalimab is safe and effective in the treatment of wAIHA.
Dr. Benitez is currently building a comprehensive translational research program in which he hopes to study the role of brain-gut-microbiome and microbiome-mucosal interactions in the development of functional GI and motility disorders.
The LUNA 3 study is for teenagers and adults (ages 12 and up) with primary immune thrombocytopenia (ITP) for which standard medications are no longer working.
ICON 3 is a prospective, open label, randomized, multi-center phase 3 clinical trial comparing eltrombopag with the enrolling physician’s choice of front line therapy.
Conducting clinical and translational research studies that will help scientists, physicians, and patients better understand autoimmune and gluten-related disorders.
